



PAUL BOSTON

Features, pp 21, 24

NEWS

- 1 Scientists are urged to oppose new US legislation that will put research studies behind a paywall
Scientific misconduct is worryingly prevalent across the UK, shows *BMJ* survey
- 2 Trusts will not be allowed to exclude drugs approved by NICE from formularies, says Lansley
DH tells women not to remove implants unless they have symptoms
GPs support withdrawal of health reform bill
- 3 Questions remain over safety and effectiveness of oseltamivir (Tamiflu)
NHS compensation fund gets £185m bailout until April as claims rise by 30% in a year
- 4 GSK and two doctors are fined for malpractice during vaccine trial
Staging anorexia nervosa could improve outcomes
- 5 Cardiovascular researcher fabricated data in studies of red wine benefits
GMC suspends flu vaccine investigator for research fraud
- 6 Portuguese health system is still too reliant on emergency care
US incident reporting systems do not capture most adverse events
Scotland introduces record of ethnicity on death certificates



RESEARCH

RESEARCH HIGHLIGHTS:

- 13 The pick of *BMJ* research papers this week
- 14 RESEARCH NEWS
- 16 Effectiveness of strategies incorporating training and support of traditional birth attendants on perinatal and maternal mortality: meta-analysis
Amie Wilson et al
◉ EDITORIAL, p 9
- 17 Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study
Birthplace in England Collaborative Group
- 18 Timing of onset of cognitive decline: results from Whitehall II prospective cohort study
Archana Singh-Manoux et al
◉ EDITORIAL, p 10
- 19 Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
Derek J Rosario et al
◉ EDITORIAL, p 11

COMMENT

EDITORIALS

- 7 Alcohol and drug problems in older people
Chris Holmwood
 - 9 Traditional birth attendants are an effective resource
Ellen Hodnett
◉ RESEARCH, p 16
- 
- 10 How early can cognitive decline be detected?
Francine Grodstein
◉ RESEARCH, p 18
 - 11 Optimising prostate biopsy
Bob Djavan and Bernardo Rocco
◉ RESEARCH, p 19
 - 12 Triage and patient safety in emergency departments
Sven Oredsson

FEATURES

- 20 *BMJ* winter appeal
Lifebox: give a little, help a lot
- 21 The greening of medicine
Ray Moynihan explores early preparations for a low carbon health system
- 24 Reducing greenhouse gas emissions: on target?
The NHS has had some success in reducing its emissions, but John Appleby finds there is still a long way to go to meet government targets

ANALYSIS

- 26 Evidence and desperation in off-label prescribing: recombinant factor VIIa
Wendy Lipworth and colleagues explore why clinicians prescribe recombinant factor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this matters



Articles appearing in this print journal have already been published on *bmj.com*, and the version in print may have been shortened. *bmj.com* also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on *bmj.com*.

Please cite all articles by year, volume, and locator (rather than page number), eg *BMJ* 2012; 344:d286.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.

100% recycled

The *BMJ* is printed on 100% recycled paper (except the cover)



A classic medical photostory, p 37

COMMENT

LETTERS

- 29 Metal on metal hip implants; Mobile phones: unhelpful apps; NICE and thromboembolism
- 30 *BMJ* Christmas appeal
- 31 Death can be our friend
- 32 The Grim Reaper's walking speed; Orthopaedic surgeons; Materials for hernia repair

OBSERVATIONS

YANKEE DOODLING

- 33 Does nicotine replacement really help smokers quit? Douglas Kamerow

MEDICINE AND THE MEDIA

- 34 Show us the evidence for telehealth Margaret McCartney

VIEWS AND REVIEWS

PERSONAL VIEW

- 35 Does anyone understand the government's plan for the NHS? Martin McKee

REVIEW OF THE WEEK

- 36 *The Iron Lady* Desmond O'Neill

BETWEEN THE LINES

- 37 *Heart and science* Theodore Dalrymple

MEDICAL CLASSICS

- 37 *Country Doctor* by W Eugene Smith John Quin



The Iron Lady: sympathetic treatment of dementia, p 36

OBITUARIES

- 38 Peter Richards, and others

LAST WORDS


- 51 *Bad medicine: medical nutrition* Des Spence
- Whose health and safety? Mary E Black

EDUCATION

CLINICAL REVIEW

- 40 *Diagnosis and management of ANCA associated vasculitis*

Annelies Berden et al



PRACTICE

GUIDELINES

- 45 *Donor identification and consent for deceased organ donation: summary of NICE guidance* K Chamberlain et al

EASILY MISSED?

- 47 *Multiple myeloma* Danny C Hsu et al

ENDGAMES

- 50 Quiz page for doctors in training

MINERVA

- 52 *Poor diet, alcohol consumption, smoking and physical inactivity, and other stories*

CAREER FOCUS, JOBS AND COURSES APPEAR AFTER P 50

21 January 2012 Vol 344

The Editor, *BMJ*BMA House, Tavistock Square,
London WC1H 9JR

Email: editor@bmj.com

Tel: +44 (0)20 7387 4410

Fax: +44 (0)20 7383 6418

BMA MEMBERS' INQUIRIES

Email: membership@bma.org.uk

Tel: +44 (0)20 7383 6642

BMJ CAREERS ADVERTISING

Email: sales@bmjcareers.com

Tel: +44 (0)20 7383 6531

DISPLAY ADVERTISING

Email: sales@bmjgroup.com

Tel: +44 (0)20 7383 6386

REPRINTS

UK/Rest of world

Email: ngurneyrandall@bmjgroup.com

Tel: +44 (0)20 8445 5825

USA

Email: mfogler@medicalreprints.com

Tel: +1 (856) 489 4446

SUBSCRIPTIONS

BMA Members

Email: membership@bma.org.uk

Tel: +44 (0)20 7383 6642

Non-BMA Members

Email: support@bmjgroup.com

Tel: +44 (0)20 7383 6270

OTHER RESOURCES

For all other contacts:

resources.bmj.com/bmj/contact-us

For advice to authors:

resources.bmj.com/bmj/authors

To submit an article:

submit.bmj.com



The BMJ is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the *BMJ*. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The *BMJ* follows guidelines on editorial independence produced by the World Association of Medical Editors (www.wame.org/wamestmt.htm#independence) and the code on good publication practice produced by the Committee on Publication Ethics (www.publicationethics.org.uk/guidelines/).

The *BMJ* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the *BMJ* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2012
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the *BMJ*

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to *BMJ*, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796.

Weekly

Printed by Polestar Limited



YUI MOK/PAP

PICTURE OF THE WEEK

Protesters outside The Harley Medical Group offices call for private clinics to replace PIP breast implants free. The government has said the NHS would remove and replace the implants without charge if patients that the NHS had operated on remained concerned. The Harley Medical Group fitted more of the implants than any other UK firm but said it will not replace them free of charge because the cost would put the firm out of business. Read Marge Berer's blog "The breast implant fiasco: a scandal of private medicine" on [bmj.com](http://bit.ly/xzQPCQ) at <http://bit.ly/xzQPCQ>

► NEWS, p 2

MOST READ ON BMJ.COM

Timing of onset of cognitive decline: results from Whitehall II prospective cohort study

Orthopaedic surgeons: as strong as an ox and almost twice as clever? Multicentre prospective comparative study

Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

CORRECTION

In the Week in Numbers in the print issue of 17 December 2011 we reported that 1 in 3333 people in the United Kingdom had experienced anaphylaxis. We should have said 1 in 1333, as given in the Practice article in the same print issue (*BMJ* 2011;343:d7595).

BMJ.COM POLL

Last week we asked, "Should doctors be able to self prescribe?"

65% voted yes (total 1614 votes cast)

This week's poll asks, "Should public funds pay when private healthcare goes wrong?"

bmj.com

► BMJ 2012;344:e306

RESPONSE OF THE WEEK

"The simplifying assumptions about the efficacy of peer review and professional ethics and responsibility fail miserably when the emperor is discovered marching around buck naked"

John H Noble Jr, emeritus professor, Georgetown, Texas, USA, in response to "Research misconduct is widespread and harms patients"

(*BMJ* 2012;344:e14)

EDITOR'S CHOICE

Saving carbon and money

Some saving will come from simply turning off lights and machines that are not being used. But there are other big ticket items

There's a certain irony in healthcare's substantial contribution to greenhouse gas emissions, given that climate change has been called the greatest threat to public health of the 21st century. The UK is among the world's lowest carbon emitters relative to gross domestic product, says John Appleby (p 24), and is also the only country committed to a legally binding reduction in emissions of 80% by 2050. So that's something to feel good about. Except that getting there is going to be a huge challenge, and healthcare is going to have to play its part.

Ray Moynihan describes how patients and professionals are taking the initiative, trying to save both carbon and money (p 21). An NHS Sustainability Day is planned for March 28, bringing together a raft of activities across the UK. If you want to find out more or to volunteer to help, join the discussion on doc2doc (<http://bit.ly/ygLy2t>).

Some saving will come from simply turning off lights and machines that are not being used. But there are other big ticket items. Pharmaceuticals account for about 22% of NHS emissions, according to the NHS Sustainable Development Unit. Its director, David Pencheon, says this is because the drugs are highly refined in big factories and then moved around the world. And because we waste a lot of them.

This high carbon contribution is yet another reason to make sure we make rational decisions on which drugs to use. This week sees the return to the knotty matter of oseltamivir (Tamiflu), the drug on which governments around the world have spent billions of dollars—and tonnes of carbon—because of claims that it reduces transmission, symptoms, and complications of influenza. Two years ago in these pages the drug's manufacturer, Roche, promised to make the trial data available, after

Cochrane reviewers declined to judge oseltamivir's effectiveness on the basis of unpublished Roche-funded trials (*BMJ* 2009;339:b5405). But the Cochrane reviewers believe that what Roche has delivered is inadequate to answer their research question ([doi:10.1136/bmj.d7898](https://doi.org/10.1136/bmj.d7898)). Because of a host of inconsistencies in what they have unearthed, they base their latest Cochrane update on only those trials for which they could read the full clinical study report. Twenty-two thousand pages later, they conclude that the drug shortens duration of symptoms, but there's insufficient trial evidence that it reduces complications (*Cochrane Database Syst Rev* 2012;1:CD008965).

In a linked investigation, Deborah Cohen shows how different regulators took different approaches to the data ([doi:10.1136/bmj.e458](https://doi.org/10.1136/bmj.e458)). The European Medicines Agency did not obtain the full study reports on oseltamivir and, along with the US Centers for Disease Control, continues to say the drug reduces complications when given to healthy adults. The US Food and Drugs Administration analysed more of the data and says this is not the case. The EMA has told the *BMJ* that it plans to start publishing reports for all drugs submitted for approval in the next few years. This will be a huge advance, putting the EMA ahead of its US counterpart perhaps for the first time.

Still, we're a long way from where we need to be. Disagreements between regulators highlight an absurd situation. In a globalised world, and given the scale of the challenge of data review, regulators need to cooperate and pool their limited resources. Otherwise we will continue to waste money and risk people's health on drugs that don't work.

Fiona Godlee, editor, BMJfgodlee@bmj.com

Cite this as: *BMJ* 2012;344:e488

► To receive Editor's Choice by email each week, visit bmj.com/cgi/customalert

Twitter

► Follow the editor, Fiona Godlee, at twitter.com/fgodlee and the *BMJ*'s latest at twitter.com/bmj_latest

Join your colleagues.

BMJ Masterclasses

masterclasses.bmj.com

